Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Mutations01:39

Mutations

Overview
Mutations01:39

Mutations

Overview
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Out of Distribution Generalization via Interventional Style Transfer in Single-Cell Microscopy.

Conference on Computer Vision and Pattern Recognition Workshops. IEEE Computer Society Conference on Computer Vision and Pattern Recognition. Workshops·2026
Same author

The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease.

medRxiv : the preprint server for health sciences·2026
Same author

Disease burden of untreated thymidine kinase 2 deficiency: insights from a large patient dataset.

Brain communications·2026
Same author

Efficacy and safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency.

Brain communications·2026
Same author

Enrichment of Rare Mitochondrial DNA Variants Among Individuals With Kidney Disease Reveals Undiagnosed Mitochondrial Disease.

Kidney international reports·2026
Same author

Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements.

European journal of neurology·2026

Related Experiment Video

Updated: Jul 16, 2026

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Mutations in coenzyme Q10 biosynthetic genes.

Salvatore DiMauro1, Catarina M Quinzii, Michio Hirano

  • 1Department of Neurology, Columbia University Medical Center, New York, New York, USA. sd12@columbia.edu

The Journal of Clinical Investigation
|March 3, 2007
PubMed
Summary

Coenzyme Q10 (CoQ10) deficiency, though known since 1989, is now better understood with identified molecular defects. Early diagnosis and oral CoQ10 supplementation can benefit patients with primary or secondary CoQ10 deficiency.

More Related Videos

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

Related Experiment Videos

Last Updated: Jul 16, 2026

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess
07:35

Assessment of Open Probability of the Mitochondrial Permeability Transition Pore in the Setting of Coenzyme Q Excess

Published on: June 1, 2022

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools
05:27

Inner Mitochondrial Membrane Sensitivity to Na+ Reveals Partially Segmented Functional CoQ Pools

Published on: July 20, 2022

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Background:

  • Coenzyme Q10 (CoQ10) deficiency, first described in 1989, presents diverse clinical syndromes.
  • Understanding of CoQ10 deficiency has advanced with the recent identification of molecular defects.

Discussion:

  • Molecular defects in three of nine CoQ10 biosynthesis genes are linked to severe, early-onset encephalomyopathies.
  • Defects in the remaining six genes are anticipated to cause similar clinical presentations.
  • Primary and secondary CoQ10 deficiencies are being elucidated, highlighting the importance of genetic analysis.

Key Insights:

  • Recent studies identify specific gene defects responsible for CoQ10 biosynthesis.
  • Early-onset encephalomyopathies are associated with identified molecular defects in CoQ10 pathways.
  • CoQ10 deficiency can be primary or secondary, impacting clinical presentation and treatment.

Outlook:

  • Further research is expected to identify defects in the remaining CoQ10 biosynthesis genes.
  • Increased awareness of CoQ10 deficiency is crucial for timely diagnosis and intervention.
  • Oral CoQ10 supplementation shows potential therapeutic benefits for affected individuals.